Early detection of nebivolol-induced hepatotoxicity

• Anna M. Torunova Department of Cardiology and Functional Diagnostic, Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education, Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of the Russian Federation, Irkutsk, Russia https://orcid.org/0000-0001-9588-1709 (unauthenticated)
• Victoria V. Kireeva Outpatient Department, Clinical Hospital of Irkutsk Scientific Centre of the Siberian Branch of the Russian Academy of Sciences, Irkutsk, Russia https://orcid.org/0000-0003-3696-9799 (unauthenticated)
• Ilia S. Kurganskii Research Centre of Translational Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, China https://orcid.org/0000-0003-4386-5162 (unauthenticated)

Abstract

Introduction: Nebivolol, a third-generation selective beta1-adrenergic receptor antagonist possessing vasodilatory properties, is characterised by a favourable safety profile. However, isolated cases of drug-induced liver injury (DILI) associated with its use have been documented in the literature.
Case description: We present a case of hepatotoxicity in a 58-year-old female patient with a history of arterial hypertension, obesity and impaired glucose tolerance. Eight weeks after initiating nebivolol therapy (2.5 mg daily), a significant elevation in liver enzymes was observed: alanine aminotransferase (134.5 U/l), aspartate aminotransferase (118.1 U/l) and alkaline phosphatase (182.1 U/l), compared to previously normal baseline values. After excluding other potential causes (viral hepatitis, alcohol consumption, biliary obstruction), nebivolol was discontinued. Subsequent clinical and laboratory improvement was noted: transaminase levels decreased significantly within two weeks, and biochemical parameters had almost completely normalised after two months. The Naranjo Adverse Drug Reaction Probability Scale score was 7, indicating a probable causal relationship. Subsequent replacement of nebivolol with metoprolol did not result in recurrent hepatic dysfunction.
Conclusion: This case substantiates the potential for idiosyncratic mixed-type hepatotoxicity associated with nebivolol administration. Although rare, this report underscores the importance of clinical vigilance and the consideration of DILI in cases of unexplained liver enzyme elevations in patients receiving this agent. Monitoring of liver function during the initial months of therapy is advisable, particularly in patients with underlying comorbidities.

View the entire article

• HTML
• PDF

Keywords

References

1. Ginghina ER, Biondi-Zoccai G, Vitali A, Di Napoli LF, Frati G. Nebivolol in the therapeutic landscape of heart failure: Mechanisms and clinical outcomes. Vascul Pharmacol 2025;162:107562. doi: 10.1016/j.vph.2025.107562
2. Seleme VB, Marques GL, Mendes AEM, Rotta I, Pereira M, Júnior EL, et al. Nebivolol for the treatment of essential systemic arterial hypertension: a systematic review and meta-analysis. Am J Cardiovasc Drugs 2021;21:165–180. doi: 10.1007/s40256-020-00422-0
3. Hanif N, Zamir A, Imran I, Saeed H, Majeed A, Rehman AU. et al. Clinical pharmacokinetics of nebivolol: a systematic review. Drug Metab Rev 2023;55:428–440. doi: 10.1080/03602532.2023.2271195
4. Unal O, Erzurumlu Y, Asci H, Gunduru Acar B, Bedir M, Ozmen O. Nebivolol protects the liver against lipopolysaccharide-induced oxidative stress, inflammation, and endoplasmic reticulum-related apoptosis through Chop and Bip/GRP78 signaling. Naunyn Schmiedebergs Arch Pharmacol 2024;397:5899–5907. doi: 10.1007/s00210-024-02990-3
5. Srour L, Ali M, Karam K, Fiani E. Nebivolol-induced hepatoxicity: a case report. Eur J Case Rep Intern Med 2024;11:004866. doi: 10.12890/2024_004866
6. Kunutsor SK, Abbasi A, Adler AI. Gamma-glutamyl transferase and risk of type II diabetes: an updated systematic review and dose-response meta-analysis. Ann Epidemiol 2014;24:809–816. doi: 10.1016/j.annepidem.2014.09.001
7. Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol 2021;116:878–898. doi: 10.14309/ajg.0000000000001259
8. LiverTox: Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245. doi: 10.1038/clpt.1981.154